Eli Lilly paused trial of antibody drug Trump touted as COVID-19 ‘cure’ over safety concern
On Oct. 13, 2020, Eli Lilly announced that the government-sponsored clinical trial of its COVID-19 antibody treatment similar…
-
-
Johnson & Johnson temporarily paused all dosing in Janssen COVID-19 vaccine candidate clinical trials
On Oct. 12, 2020, Johnson & Johnson announced temporarily paused further dosing in all our COVID-19 vaccine candidate…
-
NIH clinical trial testing hyperimmune intravenous immunoglobulin plus remdesivir to treat COVID-19 began
On Oct. 8, 2020, a clinical trial to test the safety, tolerability and efficacy of a combination treatment…
-
FDA awarded grants to fund clinical trials to advance development of products for treatment of rare diseases
On Oct. 8, 2020, The U.S. Food and Drug Administration (FDA) announced that it has awarded 12 new…
-
Caladrius Biosciences opened study of CLBS119 to repair COVID-19-induced lung damage
On Oct. 8, 2020, Caladrius Biosciences announced that it had opened its proof-of-concept study of CLBS119 as a…
-
Rentschler Biopharma contributed to manufacturing of COVID-19 mRNA vaccine
On Oct. 7, 2020, Rentschler Biopharma announced an agreement to serve as CDMO partner for BioNTech. As an…
-
HHS funded development of needle-free vaccine administration technology
On Oct. 6, 2020, the U.S. Department of Health and Human Services (HHS) announced funding of a patch…
-
AIM ImmunoTech announced approval to enroll COVID-19 ‘long haulers’ in AMP-511 ME/CFS clinical trial of Ampligen
On Oct. 6, 2020, AIM ImmunoTech announced that it had received Institutional Review Board approval for the expansion…
-
BioNTech and Pfizer initiated a rolling submission to EMA for SARS-CoV-2 vaccine candidate BNT162b2
On Oct. 6, 2020, Pfizer and BioNTech announced the initiation of a rolling submission to the European Medicines…
-
Hydroxychloroquine showed no benefit in COVID-19 prevention
On Sept. 30, 2020, researchers from the Perelman School of Medicine at the University of Pennsylvania reported results…
-
Windtree announced FDA acceptance of IND application for phase 2 clinical trial studying KL4 Surfactant in acute lung injury in adults with COVID-19
On Sept. 29, 2020, Windtree Therapeutics announced that U.S. Food and Drug Administration (FDA) has accepted its Investigational…
-
Tonix Pharma completed the purchase of a facility to house advanced development center for vaccine programs
On Sept. 28, 2020, Tonix Pharmaceuticals announced that it had completed the purchase a 40,000 square foot facility…
-
Sinovac commenced phase III clinical trials for COVID-19 vaccine candidate in Turkey
On Sept. 22, 2020, Sinovac Biotech announced that it had recently commenced phase III clinical trials for its…
-
Lilly announced proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting
On Sept. 16, 2020, Eli Lilly announced proof of concept data from an interim analysis of the BLAZE-1…
-
New anti-infective drugs had a 14% speed advantage vs other drugs from 2000-2019
On Sept. 15, 2020, the Tufts Center for the Study of Drug Development reported that new anti-infective drugs…
-
Vaxart announced FDA clearance of IND application for oral COVID-19 vaccine
On Sept. 14, 2020, Vaxart announced that the U.S. Food and Drug Administration (FDA) has completed its review…
-
Mateon global study for Artemisinin intervention against COVID-19 cleared for patient enrollment in India
On Sept. 14, 2020, Mateon Therapeutics announced that its global study based on its ARTI-19 protocol for Artemisinin…
-
RECOVERY COVID-19 phase 3 trial evaluated Regeneron’s REGN-COV2 investigational antibody cocktail in the UK
On Sept. 14, 2020, Regeneron and the University of Oxford announced that RECOVERY (Randomised Evaluation of COVid-19 thERapY),…
-
MediciNova announced intranasal RS virus vaccine vuccessfully induced neutralizing antibodies against RS virus in mice
On Sept. 11, 2020, MediciNova announced that BioComo, co-developer of MediciNova’s SARS-CoV-2 vaccine for COVID-19, announced that its…
-
NIH ACTIV initiative launched adaptive clinical trials of blood-clotting treatments for COVID-19
On Sept. 10, 2020, the National Institutes of Health launched two of three adaptive Phase 3 clinical trials…
-
AstraZeneca Oxford SARS-CoV-2 vaccine, AZD1222, COVID-19 vaccine trials temporary paused
On Sept. 9, 2020, as part of the ongoing randomised, controlled clinical trials of the AstraZeneca Oxford coronavirus…
-
Johnson & Johnson announced COVID-19 investigational vaccine candidate prevents severe clinical disease in hamsters
On Sept. 3, 2020, data from Janssen’s lead SARS-CoV-2 investigational vaccine candidate, Ad26.COV2.S, prevented severe clinical disease in…
-
Sanofi and GSK initiated Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate
On Sept. 3, 2020, Sanofi and GSK announced the start of the Phase 1/2 clinical trial for their…
-
Novavax announced publication of phase 1 data for COVID-19 vaccine candidate in The New England Journal of Medicine
On Sept. 2, 2020, Novavax announced the publication in The New England Journal of Medicine of Phase 1…
-
MediciNova announced development progress on intranasal formulation of SARS-CoV-2 vaccine for COVID-19
On Sept. 1, 2020, MediciNova announced development progress on its intranasal SARS-CoV-2 vaccine for COVID-19 utilizing BC-PIV, a…
-
Phase 3 clinical testing in the US of AstraZeneca COVID-19 vaccine candidate began
On Aug. 31, 2020, a multi-site, Phase 3 clinical trial evaluating an investigational COVID-19 vaccine known as AZD1222…
-
The US Dept of Veterans Affairs anounced new clinical trial for Veterans with COVID-19
On Aug. 28, 2020, the U.S. Department of Veterans Affairs (VA) announced a new clinical trial to study…
-
COVID-19 drug candidate Brilacidin achieved a selectivity index among the highest reported
On Aug. 24, 2020, Innovation Pharma reported receiving additional data from a U.S. Regional Biocontainment Laboratory (RBL) based…
-
Novavax initiated phase 2 portion of phase 1/2 clinical trial of COVID-19 vaccine
On Aug. 24, 2020, Novavax announced that the first volunteers were enrolled in the Phase 2 portion of…
-
NIH delivered $4.3 million to support convalescent plasma clinical trial
On Aug. 18, 2020, the National Institutes of Health (NIH) awarded Albert Einstein College of Medicine and Montefiore…
